Characterization of Human Liver Cytochrome P-450 Enzymes Involved in the O-demethylation of a New P-glycoprotein Inhibitor HM-30181Footnote∗

∗This work was supported by a Korean Health R&D project from the Ministry of Health and Welfare, Republic of Korea (HMP-01-PJ1-PG4-01PT01-00).

REFERENCES

• Abu-Quare , A. W. , Elmasry , E. and Abou-Donia , M. B. 2003 . A role for P-glycoprotein in environmental toxicology . J. Toxicol. Environ. Health B , 6 : 279 – 288 .
   PubMed Web of Science ®Google Scholar
• Bardelmeijer , H. A. , Ouwehand , M. , Beijnen , J. H. , Schellens , J. H. M. and van Tellingen , O. 2004 . Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice . Invest. New Drugs , 22 : 219 – 229 .
   PubMed Web of Science ®Google Scholar
• Baldwin , S. J. , Bloomer , J. C. , Smith , G. J. , Ayrton , A. D. , Clarke , S. E. and Chenery , R. J. 1995 . Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9 . Xenobiotica , 25 : 261 – 270 .
   PubMed Web of Science ®Google Scholar
• Dierks , E. A. , Stams , K. R. , Lim , H. K. , Cornelius , G. , Zhang , H. and Ball , S. E. 2001 . A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry . Drug Metab. Dispos. , 29 : 23 – 29 .
   PubMed Web of Science ®Google Scholar
• Ford , J. M. 1996 . Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitizers . Eur. J. Cancer , 32A : 991 – 1001 .
   PubMed Web of Science ®Google Scholar
• Fracasso , P. M. , Goldstein , L. J. , de Alwis , D. P. , Rader , J. S. , Arquette , M. A. , Goodner , S. A. , Wright , L. P. , Fears , C. L. , Gazak , R. J. , Andre , V. A. M. , Burgess , M. F. , Slapak , C. A. and Schellens , J. H. M. 2004 . Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies . Clin. Cancer Res. , 10 : 7220 – 7228 .
   PubMed Web of Science ®Google Scholar
• Gottesman , M. M. , Fojo , T. and Bates , S. E. 2002 . Multidrug resistance in cancer: Role of ATP-dependent transporters . Natl. Rev. Cancer , 2 : 48 – 58 .
   PubMed Web of Science ®Google Scholar
• Lanning , C. L. , Fine , R. L. , Sachs , C. W. , Rao , U. S. , Corcoran , J. J. and Abou-Donia , M. B. 1996 . Chlorpyrifos oxon interacts with the mammalian multidrug resistance protein, P-glycoprotein . J. Toxicol. Environ. Health , 47 : 395 – 407 .
   PubMed Web of Science ®Google Scholar
• Lehne , G. 2000 . P-glycoprotein as a drug target in the treatment of multidrug resistant cancer . Curr. Drug Targets , 1 : 85 – 99 .
   PubMed Web of Science ®Google Scholar
• Lillibridge , J. H. , Liang , B. H. , Kerr , B. M. , Webber , S. , Quart , B. , Shetty , B. and Lee , C. A. 1998 . Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate . Drug Metab. Dispos. , 26 : 609 – 616 .
   PubMed Web of Science ®Google Scholar
• Newton , D. J. , Wang , R. W. and Lu , A. Y. 1995 . Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes . Drug Metab. Dispos. , 23 : 154 – 158 .
   PubMed Web of Science ®Google Scholar
• Paek , I. B. , Ji , H. Y. , Kim , M. S. , Lee , K. S. and Lee , H. S. 2006a . Simultaneous determination of paclitaxel and a new P-glycoprotein inhibitor HM-30181 in rat plasma by liquid chromatography with tandem mass spectrometry . J. Sep. Sci. , 29 : 628 – 634 .
   PubMed Web of Science ®Google Scholar
• Paek , I. B. , Ji , H. Y. , Kim , M. S. , Lee , K. S. and Lee , H. S. 2006b . Metabolism of a new P-glycoprotein inhibitor HM-30181 in rats using liquid chromatography/electrospray mass spectrometry . Rapid Comm. Mass Spectrom. , 20 : 1457 – 1462 .
   PubMed Web of Science ®Google Scholar
• Pusztai , L. , Wagner , P. , Ibrahim , N. , Rivera , E. , Theriault , R. , Booser , D. , Symmans , F.W. , Wong , F. , Blumenschein , G. , Fleming , D. R. , Rouzier , R. , Boniface , G. and Hortobagyi , G. N. 2005 . Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma . Cancer , 104 : 682 – 691 .
   PubMed Web of Science ®Google Scholar
• Raderer , M. and Scheithauer , W. 1993 . Clinical trials of agents that reverse multidrug resistance. A literature review . Cancer , 72 : 3553 – 3563 .
   PubMed Web of Science ®Google Scholar
• Raspollini , M. R. , Pinzani , P. , Pazzagli , M. , Baroni , G. , Taddei , A. , Amunni , G. , Villanucci , A. and Taddei , G. L. 2002 . Multidrug resistance in ovarian cancer: comparing an immunocytochemical study and ATP-tumor chemosensitivity assay . J. Chemother. , 14 : 518 – 525 .
   PubMed Web of Science ®Google Scholar
• Richter , T. , Schwab , M. , Eichelbaum , M. and Znager , U. M. 2005 . Inhibition of human CYP2B6 by N, N′, N′′-triethylenethiophosphoramide is irreversible and mechanism-based . Biochem. Pharmacol. , 69 : 517 – 524 .
   PubMed Web of Science ®Google Scholar
• Sandler , A. , Gordon , M. , de Alwis , D. P. , Pouliquen , I. , Green , L. , Marder , P. , Chaudhary , A. , Fife , K. , Battiato , L. , Sweeney , C. , Jordan , C. , Burgess , M. and Slapak , C. A. 2004 . A phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy . Clin. Cancer Res. , 10 : 3265 – 3272 .
   PubMed Web of Science ®Google Scholar
• Sesardic , D. , Boobis , A. R. , Murray , B. P. , Murray , S. , Segura , J. , de la Torre , R. and Davies , D. S. 1990 . Furafylline is a potent and selective inhibitor of cytochrme P450IA2 in man . Br. J. Clin. Pharmacol. , 29 : 651 – 663 .
   PubMed Web of Science ®Google Scholar
• Shimada , T. , Yamazaki , H. , Mimura , M. , Inui , Y. and Guengerich , F. P. 1994 . Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians . J. Pharmacol. Exp. Ther. , 270 : 414 – 423 .
   PubMed Web of Science ®Google Scholar
• Sikic , B. I. 1997 . Pharmacologic approaches to reversing multidrug resistance . Semin. Hematol. , 34 ( 4 suppl. 5 ) : 40 – 47 .
   PubMed Web of Science ®Google Scholar
• Sparreboom , A. and Nooter , K. 2000 . Does P-glycoprotein play a role in anticancer drug pharmacokinetics? . Drug Resist. Update , 3 : 357 – 363 .
   PubMed Web of Science ®Google Scholar
• Suzuki , H. , Kneller , M. B. , Haining , R. L. , Trager , W. F. and Rettie , A. E. 2002 . (+)-N-3-Benzylnirvanol and (–)-N-3-benzyl-phenobarbital: New potent and selective in vitro inhibitors of CYP2C19 . Drug Metab. Dispos. , 30 : 235 – 239 .
   PubMed Web of Science ®Google Scholar
• Thomas , H. and Coley , H. M. 2003 . Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein . Cancer Control , 10 : 159 – 165 .
   PubMedGoogle Scholar
• von Moltke , L. L. , Greenblatt , D. J. , Schmider , J. , Duan , S. X. , Wright , C. E. , Harmatz , J. S. and Shader , R. I. 1996 . Midazolam hydroxylation by human liver microsomes in vitro: Inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents . J. Clin. Pharmacol. , 36 : 783 – 791 .
   PubMed Web of Science ®Google Scholar
• von Moltke , L. L. , Greenblatt , D. J. , Grassi , J. M. , Granda , B. W. , Duan , S. X. , Fogelman , S. M. , Daily , J. P. , Harmatz , J. S. and Shader , R. I. 1998 . Protease inhibitors as inhibitors of human cytochromes P450: High risk associated with ritonavir . J. Clin. Pharmacol. , 38 : 106 – 111 .
   PubMed Web of Science ®Google Scholar
• Walker , J. , Martin , C. and Callaghan , R. 2004 . Inhibition of P-glycoprotein function by XR-9576 in a solid tumor model can restore anticancer drug efficacy . Eur. J. Cancer , 40 : 594 – 605 .
   PubMed Web of Science ®Google Scholar
• Walsky , R. L. , Obach , R. S. , Gaman , E. A. , Gleeson , J. P. R. and Protor , W. R. 2005 . Selective inhibition of human cytochrome P4502C8 by montelukast . Drug Metab. Dispos. , 33 : 413 – 418 .
   PubMed Web of Science ®Google Scholar
• Wang , J. S. , Wen , X. , Backman , J. T. , Taavitsainen , P. , Neubonnen , P. J. and Kivisto , K. T. 1999 . Midazolam α-hydroxylation by human liver microsomes in vitro: Inhibition by calcium channel blockers, itraconazole and ketoconazole . Pharmacol. Toxicol. , 85 : 157 – 161 .
   PubMedGoogle Scholar
• Watkins , P. B. , Wrighton , S. A. , Mauel , P. , Schuets , E. G. , Mendezpicon , G. , Parker , G. A. and Guzelian , P. S. 1985 . Identification of an inducible form of cytochrome P-450 in human liver . Proc. Nat. Acad. Sci. USA , 82 : 6310 – 6314 .
   PubMed Web of Science ®Google Scholar
• Wrighton , S. A. , Brian , W. R. , Sari , M. A. , Iwasaki , M. , Guengerich , F. P. , Raucy , J. L. , Molowa , D. T. and Vandenbranden , M. 1990 . Studies on the expression and metabolic capabilities of human liver cytochrome P-450 IIIA4 (HLp 3) . Mol. Pharmacol. , 38 : 207 – 213 .
   PubMed Web of Science ®Google Scholar
• Wrighton , S. A. and Thummel , K. E. 2000 . “ CYP3A. In Metabolic drug interactions ” . Edited by: Levy , R. H. , Thummel , K. E. , Trager , W. F. , Hansten , P. D. and Eichelbaum , M. 115 – 133 . Philadelphia : Lippincott Williams & Wilkins .
   Google Scholar
• Yun , C. H. , Shimada , T. and Guengerich , F. P. 1991 . Purification and characterization of human liver microsomal cytochrome P450 2A6 . Mol. Pharmacol. , 40 : 679 – 685 .
   PubMed Web of Science ®Google Scholar